Treatment of Human Chronic Fascioliasis with Triclabendazole: Drug Efficacy and Serologic Response

Werner Apt Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Werner Apt in
Current site
Google Scholar
PubMed Close
,
Ximena Aguilera Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Ximena Aguilera in
Current site
Google Scholar
PubMed Close
,
Flavio Vega Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Flavio Vega in
Current site
Google Scholar
PubMed Close
,
Claudio Miranda Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Claudio Miranda in
Current site
Google Scholar
PubMed Close
,
Ines Zulantay Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Ines Zulantay in
Current site
Google Scholar
PubMed Close
,
Carlos Perez Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Carlos Perez in
Current site
Google Scholar
PubMed Close
,
Melvyn Gabor Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Melvyn Gabor in
Current site
Google Scholar
PubMed Close
, and
Patricia Apt Parasitology Unit, Faculty of Medicine, Southern Campus, University of Chile, Santiago, Chile

Search for other papers by Patricia Apt in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.4269/ajtmh.1995.52.532
Volume/Issue:
Volume 52: Issue 6
Page(s):
532–535
Restricted access
Get Permissions

Between November 1990 and March 1992, 24 asymptomatic individuals in Chile with chronic hepatic fascioliasis confirmed by the presence of Fasciola hepatica eggs in feces were treated with a single oral dose of triclabendazole (10 mg/kg of body weight) after an overnight fast. Nineteen (79.2%) of 24 patients were egg-negative two months after treatment. Three of five cases with F. hepatica in feces after the first treatment were retreated and parasitologic cure was achieved. Tolerance to the drug was excellent; none of the patients had either secondary symptoms or important alterations in levels of aspartate and amino transferases, alkaline phosphatase, or bilirubin during or after treatment. Mild eosinophilia, present in 70% of the cases, persisted at least until 60 days after treatment. An enzyme-linked immunosorbent assay (ELISA) was highly effective in diagnosis and post-treatment monitoring. Before treatment, 20 (83.3%) of 24 confirmed cases had positive test results. The test results became negative by the second month of treatment in 40% of the cured cases. This percentage increased progressively, reaching 91.3% at 12 months after therapy. In the five cases in which treatment failed, the ELISA results remained positive until the end of the follow-up period (six months). In three of these cases who accepted a second round of therapy with triclabendazole six months after the first treatment, the ELISA results became negative in all three six months after parasitologic cure and remained negative until the end of the period. Due to its efficacy, excellent tolerance, and ease of administration (a single oral dose), triclabendazole appears to be the drug of choice for chronic human fascioliasis.

Author Notes

Copyright:
Copyright © 1995 by The American Society of Tropical Medicine and Hygiene 1995
Published Online:
Jun 1995
Cover The American Journal of Tropical Medicine and Hygiene
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
Past two years Past Year Past 30 Days
Abstract Views 799 338 55
Full Text Views 45 3 1
PDF Downloads 52 8 2
 
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save